CCL2 and breast cancer: Lavender et al. evaluated whether CCL2 can “entrain” naïve neutrophils to enhance tumor cell killing using three different mouse BC models, 4T1, 67NR, and PyMT, with different aggressiveness: 4T1 and PyMT cells as metastatic cells and 67NR cells as nonmetastatic cells.